Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week [MSNBC.com]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: MSNBC.com
In this articleA sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel, northern Switzerland, on Sept. 9, 2025.Fabrice Coffrini | AFP | Getty ImagessaidThe acquisition will add Exl-111, an early-stage drug candidate, to Novartis' existing allergy portfolio. It is the latest bolt-on deal in the company's attempt to offset looming patent expirations.It comes just a week afterNovartis announcedIn February, the companycompleted the acquisition of Avidity BiosciencesExcellergy's lead asset remains several years away from hitting the market. Novartis said it will pay the smaller biotech in both upfront and milestone payments, and the transaction is expected to close in the first half of 2026, subject to regulatory approvals.Novartis stock traded sideways in morning trading in Zurich. Palo Alto-based Excellergy is privately held.Stock Chart IconStock chart iconShares of Novartis are up 33% over the past 12 months.Many of the best-selling dru
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE-IgAN Study [Yahoo! Finance]Yahoo! Finance
- AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [Yahoo! Finance]Yahoo! Finance
- The Vanguard ETF Up About 28% in the Past Year That Almost Nobody Outside of Income Investors Knows [Yahoo! Finance]Yahoo! Finance
- AAVantgarde appoints Philip Lao as Senior Vice President of Business Development [TheStreet.com]TheStreet.com
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form FWP
- 2/12/26 - Form 144
- NVS's page on the SEC website